next 5 years, CDC will work with many different partners to help implement:
III trials in Thailand of an HIV vaccine based on the glycoprotein-20
antigen developed by the VaxGen company
to evaluate the effectiveness of 7-valent pneumoccocal conjugate vaccines
Herd immunity among Native American communities that have high rates
of invasive disease. This is a phase III, cluster-randomized trial
of conjugate pneumococcal vaccine conducted in collaboration with
Johns Hopkins School of Public Health.
Nasopharyngeal carriage of pneumococci in Alaska
Invasive pneumococcal disease throughout the United States, using
the Active Bacterial Core Surveillance (ABCs) system.
III trial in the Gambia of a 9-valent conjugate pneumococcal vaccine
against all-cause mortality and acute-respiratory-infection-specific
mortality, conducted in collaboration with the Medical Research Council-Gambia,
USAID, NIH, the Bill and Melinda Gates Childrens Vaccine Program,
and WHOs Vaccine Development, Vaccines and Biologicals program.
Phase I trials of two vaccines against Schistosomiasis mansoni,
conducted by the Schistosome Vaccine Development Project, a partnership
involving the Government of Egypt, CDC, NIH/NIAID, NAMRU-3, academic
centers, and private industry.
- A multisite
rotavirus vaccine trial in Southeast Asian countries using an attenuated
human rotavirus vaccine produced in India.